Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ibio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IBIO
American
8731
https://www.ibioinc.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ibio Inc
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
- Apr 5th, 2024 6:35 pm
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
- Mar 27th, 2024 11:00 am
iBio Announces $15.0 Million Private Placement
- Mar 26th, 2024 11:35 pm
12 Best Biotech Penny Stocks to Invest In
- Mar 24th, 2024 7:54 pm
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
- Feb 26th, 2024 12:45 pm
iBio Announces Participation in 23rd Annual PepTalk Conference
- Jan 16th, 2024 1:15 pm
iBio Amends and Extends Maturity of Credit Agreement
- Dec 26th, 2023 12:15 pm
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
- Dec 5th, 2023 1:00 pm
iBio Announces Reverse Stock Split
- Nov 27th, 2023 10:20 pm
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
- Nov 1st, 2023 12:24 pm
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
- Oct 10th, 2023 12:00 pm
iBio Explains Recent Filing of Registration Statement
- Oct 2nd, 2023 10:45 am
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
- Sep 27th, 2023 8:19 pm
iBio Announces Amendment to Credit Agreement with Woodforest
- Sep 21st, 2023 8:05 pm
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
- Aug 14th, 2023 8:15 pm
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
- Jun 27th, 2023 12:00 pm
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
- Jun 20th, 2023 12:25 pm
iBio Forges Research Collaboration with the National Institutes of Health
- Jun 12th, 2023 8:15 pm
iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
- Jun 6th, 2023 12:00 pm
iBio to Participate in the JMP Securities Life Sciences Conference
- May 9th, 2023 8:30 pm
Scroll